Latest Healthcare News

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.

Cleo Diagnostics has completed alpha testing of its ovarian cancer pre-surgical triage assay kits, confirming robust performance and differentiation between benign and malignant disease. The company now moves forward to assay optimisation and manufacturing scale-up, edging closer to FDA submission and commercial launch.

Universal Biosensors reports a 6% sales increase in Q1 2025, driven by strong growth in wine and veterinary biosensors, while preparing to launch its innovative water testing product later this year.

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Radiopharm Theranostics has secured Data Safety and Monitoring Committee approval to escalate dosing in its Phase 1 trial of 177Lu-RAD204, expanding patient cohorts across multiple cancer types.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

Vitura Health reports sustained revenue and EBITDA growth in Q3 FY2025, driven by recent acquisitions and operational improvements, positioning the company well for FY2026.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payable to ASX-listed CDI holders, impacting the Australian dollar equivalent of the payout.

MedAdvisor Limited has entered a non-binding agreement to sell its ANZ business division for a headline price of $35 million plus a potential earn-out, marking a significant strategic shift.

Austco Healthcare has renewed its preferred supplier agreement with a major US healthcare provider, continuing supply of its Tacera nurse call systems to 180 hospitals across 30 states. This extension builds on a lucrative five-year partnership worth over A$49 million.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.